These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 24994790)
1. A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes. de Jongste AH; van Gelder T; Bromberg JE; de Graaf MT; Gratama JW; Schreurs MW; Hooijkaas H; Sillevis Smitt PA Neuro Oncol; 2015 Jan; 17(1):145-50. PubMed ID: 24994790 [TBL] [Abstract][Full Text] [Related]
2. Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurological syndromes. van Broekhoven F; de Graaf MT; Bromberg JE; Hooijkaas H; van den Bent MJ; de Beukelaar JW; Khan NA; Gratama JW; van der Geest JN; Frens M; Benner R; Sillevis Smitt PA J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1341-4. PubMed ID: 20667866 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Bastiaansen AEM; de Jongste AHC; de Bruijn MAAM; Crijnen YS; Schreurs MWJ; Verbeek MM; Dumoulin DW; Taal W; Titulaer MJ; Sillevis Smitt PAE Neurooncol Adv; 2021; 3(1):vdab145. PubMed ID: 34693289 [TBL] [Abstract][Full Text] [Related]
4. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485 [TBL] [Abstract][Full Text] [Related]
5. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Shams'ili S; de Beukelaar J; Gratama JW; Hooijkaas H; van den Bent M; van 't Veer M; Sillevis Smitt P J Neurol; 2006 Jan; 253(1):16-20. PubMed ID: 16444604 [TBL] [Abstract][Full Text] [Related]
6. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected. Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848 [TBL] [Abstract][Full Text] [Related]
7. Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature. Raibagkar P; Ho D; Gunturu KS; Srinivasan J J Neuroimmunol; 2020 Apr; 341():577184. PubMed ID: 32058173 [TBL] [Abstract][Full Text] [Related]
8. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. Honnorat J; Cartalat-Carel S; Ricard D; Camdessanche JP; Carpentier AF; Rogemond V; Chapuis F; Aguera M; Decullier E; Duchemin AM; Graus F; Antoine JC J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):412-6. PubMed ID: 18931014 [TBL] [Abstract][Full Text] [Related]
9. Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies. de Jongste AH; de Graaf MT; Martinuzzi E; van den Broek PD; Kraan J; Lamers CH; Mallone R; Gratama JW; Sillevis Smitt PA Neuro Oncol; 2012 Jul; 14(7):841-8. PubMed ID: 22591661 [TBL] [Abstract][Full Text] [Related]
10. Quantification of circulating anti-Hu antibody in serial samples from patients with paraneoplastic neurological syndromes: possible correlation of antibody concentration and course of neurological symptoms. Rauer S; Czygan M; Kaiser R J Neurol; 2002 Mar; 249(3):285-9. PubMed ID: 11993527 [TBL] [Abstract][Full Text] [Related]
11. The use of eye-movement recording in patients with anti-Hu antibody-associated paraneoplastic neurological syndromes to objectively determine extent and course of disease. Janssen M; van Broekhoven F; Sillevis Smitt P; Frens M; van der Geest J Eur J Neurol; 2021 Jun; 28(6):2126-2132. PubMed ID: 33675135 [TBL] [Abstract][Full Text] [Related]
12. Dysautonomia in anti-Hu paraneoplastic neurological syndromes. Villagrán-García M; Farina A; Arzalluz-Luque J; Campetella L; Muñiz-Castrillo S; Benaiteau M; Peter E; Dumez P; Wucher V; Dhairi M; Picard G; Rafiq M; Psimaras D; Rogemond V; Joubert B; Honnorat J J Neurol; 2024 Jun; 271(6):3359-3369. PubMed ID: 38494470 [TBL] [Abstract][Full Text] [Related]
14. Anti-Hu antibody associated paraneoplastic neurological syndrome in a child with ganglioneuroblastoma: A rare case report and literature review. Dai YL; Xiao L; Pan Z; He GQ; Gao J; Guo X; Huang Z Medicine (Baltimore); 2024 May; 103(19):e38148. PubMed ID: 38728479 [TBL] [Abstract][Full Text] [Related]
15. Various clinical features of patients with anti-Hu associated paraneoplastic neurological syndromes: An observational study. Li J; Lin W Medicine (Baltimore); 2018 May; 97(18):e0649. PubMed ID: 29718880 [TBL] [Abstract][Full Text] [Related]
16. Imbalance in circulating T lymphocyte subsets contributes to Hu antibody-associated paraneoplastic neurological syndromes. Zhang L; Qian W; Chen Q; Yin L; Li B; Wang H Cell Immunol; 2014 Aug; 290(2):245-50. PubMed ID: 25173445 [TBL] [Abstract][Full Text] [Related]